LAKE FOREST, Ill., Jan. 19, 2016 — (Healthcare Sales & Marketing Network) — Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8… Biopharmaceuticals, Generics, Product LaunchAkorn, Buprenorphine, Naloxone, Tobramycin (Source: HSMN NewsFeed)

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)

ConclusionsA randomized controlled trial in a syringe exchange programme showed no evidence that a strength‐based case management intervention improved attendance for treatment over referral alone. Attendance rates were high in both groups. (Source: Addiction)

This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)

This study demonstrated that RBP-6000 at a 300 mg dose provides durable and potent blockade of the subjective effects and reinforcing efficacy of hydromorphone in subjects with moderate or severe opioid use disorder. (Source: Journal of Clinical Psychopharmacology)

CONCLUSIONS AND SCIENTIFIC SIGNIFICANCE: Our results indicate that alcohol and illicit substance use is associated with non-adherence to BUP-naloxone treatment, and suggests that CBT and efforts to promote abstinence from non-opioid substance use may improve adherence among African-Americans. These findings contribute to growing literature on understanding adherence to BUP-naloxone, which is critical to reduce morbidity and mortality. (Am J Addict 2016;XX:1-8).
PMID: 26749158 [PubMed – as supplied by publisher] (Source: American Journal on Addictions)

Publication date: 20 February 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 120 Author(s): Yongzhen Liu, Xiaohua Li, Allan Xu, Azmi F. Nasser, Christian Heidbreder A simple, sensitive and rapid liquid chromatography/electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS) method was developed and validated for simultaneous quantification of naloxone, buprenorphine and its metabolite norbuprenorphine in human plasma. Human plasma samples were extracted using a single step liquid–liquid extraction, and then separated on an Imtakt Unison UK-C18 column (2.1×50mm, 3μm) using alkaline mobile phases with gradient elution. All of the analytes were detected in positive ion mode using multiple reaction monitoring (MRM). The method was validated and the spe…

Publication date: 20 February 2016 Source:Journal of Pharmaceutical and Biomedical Analysis, Volume 120 Author(s): Yongzhen Liu, Xiaohua Li, Allan Xu, Azmi F. Nasser, Christian Heidbreder A simple, sensitive and rapid liquid chromatography/electrospray ionization tandem mass spectrometry (LC–ESI-MS/MS) method was developed and validated for simultaneous quantification of naloxone, buprenorphine and its metabolite norbuprenorphine in human plasma. Human plasma samples were extracted using a single step liquid–liquid extraction, and then separated on an Imtakt Unison UK-C18 column (2.1×50mm, 3μm) using alkaline mobile phases with gradient elution. All of the analytes were detected in positive ion mode using multiple reaction monitoring (MRM). The method was validated and the spe…

We present a clinical case series of four adult patients dependent on OTC codeine combination analgesics in Ireland. Cases (two males/two females, aged 44–57 years) were consuming between 12 and 72 codeine-containing tablets/day. In three cases, consumption was linked to pain, with on-going misuse reflecting dependence on codeine. Cases were initiated on buprenorphine-naloxone (Suboxone®), stabilised on doses of between 4 mg/1 mg and 14 mg/3.5 mg per day and remain on treatment without additional opioid use, as verified by drug screening reports. Although anecdotal, these cases show the potential of effective opioid assisted treatment (OAT) using buprenorphine-naloxone (Suboxone®) to successfully treat this distinct form of opioid dependence disorder. Optimal service provision sho…

(Source: Alcoholism and Drug Abuse Weekly)